Niagen Bioscience Inc

Niagen Bioscience Inc(NAGE)の株式分析

$2.520

+0.171 (+6.78%)終値時点

Loading chart…
高値
2.590
始値
2.410
出来高加重平均価格
2.50
出来高
674.21K
時価総額
—
安値
2.400
売買代金
1.69M
EV/EBITDA(TTM)
23.23

Niagen Bioscience, Inc. is a global bioscience company promoting healthy aging. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredient, Niagen, directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment comprises pharmaceutical development of its proprietary molecules for potential therapeutic applications in rare diseases and conducts research and development activities.

AI分析 of Niagen Bioscience Inc (NAGE)

中立

Currently, Niagen Bioscience, Inc. (NAGE) is trading at $2.40, significantly below its 52-week high of $7.95, which presents a potential buying opportunity. However, the stock has a low RSI of 38.77, indicating it may be oversold, but it also reflects a lack of strong buying momentum. The forward P/E ratio is 16.67, suggesting that the stock is relatively valued compared to its earnings potential. The main risk is the declining performance in its ingredient business due to increased competition, which could impact future revenue growth.

バリュエーション指標

Niagen Bioscience Inc(NAGE)の現在の予想PERは17.15で、5年平均は39.86です。

予想PER

適正
5年平均 P/E
39.86
現在のP/E
17.15
割高
66.13
割安
13.58

予想EV/EBITDA

適正
5年平均 EV/EBITDA
30.23
現在のEV/EBITDA
23.23
割高
43.26
割安
17.20

予想PSR

割安
5年平均 P/S
3.45
現在のP/S
1.22
割高
5.30
割安
1.60

Alphio AI による NAGE の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%NAGE

$14.51

シナリオ価格

基

基本

基本 · 50%NAGE

$12.61

シナリオ価格

弱

弱気

弱気 · 25%NAGE

$10.88

シナリオ価格

NAGE を保有するクジラ

S

SteelPeak Wealth, LLC

+ を保有NAGE

-5.42%

3か月リターン

イベントタイムライン

2026-11-04 (ET)

16:30:00

Rob Fried: Q3 Revenue $27.2M, Outlook for Growth in 2027

16:30:00

Company Expects E-commerce Revenue Growth of 5%-20% in 2026

2026-10-22 (ET)

09:00:00

Niagen Bioscience Launches Prescription-Only Injection Kit

2026-10-20 (ET)

09:00:00

Niagen Bioscience Launches New Tru Niagen Skincare Category

2026-10-01 (ET)

09:00:00

Niagen Bioscience Launches New Brand Campaign

ニュース

NAGE のよくある質問 — Alphio AI が回答

Niagen Bioscience, Inc. is a global bioscience company promoting healthy aging. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredient, Niagen, directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment comprises pharmaceutical development of its proprietary molecules for potential therapeutic applications in rare diseases and conducts research and development activities. It operates in the Healthcare sector.

Currently, Niagen Bioscience, Inc. (NAGE) is trading at $2.40, significantly below its 52-week high of $7.95, which presents a potential buying opportunity. However, the stock has a low RSI of 38.77, indicating it may be oversold, but it also reflects a lack of strong buying momentum. The forward P/E ratio is 16.67, suggesting that the stock is relatively valued compared to its earnings potential. The main risk is the declining performance in its ingredient business due to increased competition, which could impact future revenue growth.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める